Curative effects of everolimus-eluting stent and sirolimus-eluting stent on coronary heart disease: a Meta-analysis

LIU Xiao-xiong,XIA Hao,WAN Nian,ZHANG Yan

DOI: https://doi.org/10.3969/j.1674-4055.2013.02.005

2013-01-01

Abstract:Objective To compare the curative effect and safety of everolimus-eluting stent (EES) and sirolimus-eluting stent (SES) on coronary heart disease (CHD) . Methods The databases of PubMed, MedLine, CENTRAL and CNKI were retrieved with computers for collecting randomized controlled trials (RCT) about the comparison in the curative effect and safety of EES and SES published from Jan. 2007 to Dec. 2012. At the same time, the reference materials of included literature were retrieved manually. After rigorous evaluation on literature quality, the eligible data of RCT was extracted and given a Meta-analysis by applying RevMen5.1 software. Results There were totally 7 RCT included, and the results of Meta-analysis showed that between EES group and SES group, the rate of mortality (OR=0.98, 95% CI:0.85-1.12, P=0.75) , cardiac mortality (OR=1.05, 95% CI:0.88-1.25, P=0.57) and target lesion revascularization (TLR,OR=0.92, 95% CI:0.65-1.31, P=0.65) , and the incidence major adverse cardiovascular events (MACE, OR =0.95, 95% CI : 0.77-1.18, P =0.66) , in-stent thrombosis (OR=0.80, 95% CI:0.49-1.32, P=0.39) and in-stent restenosis (OR=0.89, 95% CI:0.26-3.04, P=0.85 ) all had no statistical difference, while the incidence of myocardial infarction was lower in EES group than that in SES group (OR=0.66, 95% CI:0.53-0.80, P<0.001) . Conclusion In the treatment of CHD with stent implantation, EES can significantly reduce the incidence of myocardial infarction, but is similar to SES in the rate of mortality, cardiac mortality and TLR, and the incidence MACE, in-stent thrombosis and in-stent restenosis.